| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Departments of Pathology [B. J. R., P. J. S-H.], Medicine-Vascular Medicine Unit [B. J. R., P. J. S-H.], and Microbiology and Immunology [P. J. S-H.], University of Rochester School of Medicine and Dentistry, Rochester, New York 14642
A hallmark of breast carcinoma is the deposition of fibrinogen (FBG)
without subsequent conversion to fibrin in the tumor stroma. In this
study, the ability of the MCF-7 human breast cancer epithelial cell
line to synthesize, secrete, and deposit FBG into the extracellular
matrix (ECM) was examined. Whereas MCF-7 cells produced low levels of
intact FBG, abundant levels of FBG intermediate complexes or degraded
A
, Bß, and
chain polypeptides were observed. Most of the Bß
chain was degraded and missing an NH2-terminal
peptide fragment. Reverse transcription-PCR analysis indicated that
only
chain mRNA was present in detectable steady-state levels,
although Southern hybridization revealed that the FBG A
, Bß, and
chain genes were intact in MCF-7 cells. Immunostaining
showed that extracellular FBG was bound to the surface of MCF-7 cells
in a punctate pattern, reminiscent of receptor binding, rather than a
fibrillar pattern characteristic of mature ECM. A similar punctate
pattern of staining was observed when MCF-7 FBG was added to
fibroblasts that normally assemble exogenous FBG into an extensive,
fibrillar ECM, suggesting that MCF-7 cells are defective in assembly of
a fibrillar ECM. The loss of FBG Bß chain NH2-terminal
peptides may contribute to the lack of intact FBG assembly in MCF-7
cells, which may further affect its ability to assemble FBG into a
fibrillar ECM. Taken together, the data suggest that endogenous
synthesis and secretion of FBG is, at least in part, the source of FBG
deposition in the ECM of breast cell carcinomas.
This article has been cited by other articles:
![]() |
H. O. Duan and P. J. Simpson-Haidaris Cell Type-specific Differential Induction of the Human {gamma}-Fibrinogen Promoter by Interleukin-6 J. Biol. Chem., May 5, 2006; 281(18): 12451 - 12457. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-J. Cheng, L.-C. Chen, K.-Y. Chien, Y.-J. Chen, J. T.-C. Chang, H.-M. Wang, C.-T. Liao, and I-H. Chen Oral Cancer Plasma Tumor Marker Identified with Bead-Based Affinity-Fractionated Proteomic Technology Clin. Chem., December 1, 2005; 51(12): 2236 - 2244. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-J. Tan, P.-Y. Tham, D. Z. L. Chan, C.-F. Chou, S. Shen, B. C. Fielding, T. H. P. Tan, S. G. Lim, and W. Hong The Severe Acute Respiratory Syndrome Coronavirus 3a Protein Up-Regulates Expression of Fibrinogen in Lung Epithelial Cells J. Virol., August 1, 2005; 79(15): 10083 - 10087. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Criscuoli, M. Nguyen, and B. P. Eliceiri Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability Blood, February 15, 2005; 105(4): 1508 - 1514. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Rybarczyk, S. O. Lawrence, and P. J. Simpson-Haidaris Matrix-fibrinogen enhances wound closure by increasing both cell proliferation and migration Blood, December 1, 2003; 102(12): 4035 - 4043. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |